Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France-Reference-Cited by-同舟云学术

Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France

Published:2023-02-10 Issue:1 Volume:26 Page:243-253
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Karampampa Korinna¹^ORCID,Zhang Wenjie²^ORCID,Venkatachalam Meena²^ORCID,Cotte Francois-Emery³^ORCID,Dhanda Devender⁴^ORCID

Affiliation:

1. Bristol Myers Squibb, Uxbridge, UK

2. Precision Health, Los Angeles, CA, USA

3. Bristol Myers Squibb, Rueil-Malmaison, France

4. Bristol Myers Squibb, Princeton, NJ, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2173466

Reference49 articles.

1. Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment

2. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

3. Celgene. ABECMA (idecabtagene vicleucel) [prescribing information]. Summit, NJ: Celgene Corporation, a Bristol-Myers Squibb Company; 2021.

4. Celgene. Abecma (idecabtagene vicleucel) [summary of product characteristics]. Utrecht, Netherlands: Celgene Europe B.V; 2021.

5. Bristol Myers Squibb. Health Canada approves ABECMATM (idecabtagene vicleucel) the first and only anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma. 2021. Available from: https://www.bms.com/ca/en/media/press-release-listing/2021-05-31-press-release.html#:∼:text=Health%20Canada%20Approves%20ABECMATM Relapsed%20and%20Refractory%20Multiple%20Myeloma&text=%E2%80%9CToday’s%20approval%20is%20an%20important i. n%20Canada%2C%E2%80%9D%20says%20Dr.Pu.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review;Value in Health;2024-08

2. A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models;PharmacoEconomics;2024-06-25

3. The new era of immunological treatment, last updated and future consideration of CAR T cell-based drugs;Pharmacological Research;2024-05

4. Evolution of Pharmacological Treatments and Associated Costs for Multiple Myeloma in the Public Healthcare System of Catalonia: A Retrospective Observational Study;Cancers;2023-11-09

5. CAR-T therapy for multiple myeloma in China. Does it make sense financially?;Journal of Medical Economics;2023-06-30